title: Patients' satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis.
abstract: OBJECTIVE
  The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients' satisfaction with the treatment must be taken into consideration.
  
  
  METHODS
  Individual interview with patients with MS regarding their satisfaction and points of view on the treatment with DMDs.
  
  
  RESULTS
  One hundred and twenty eight patients attending specialized MS Units in five different cities were interviewed. Over 80% of patients were very satisfied with the drugs in use regarding convenience and perceived benefits. The only aspect scoring lesser values was tolerability.
  
  
  CONCLUSIONS
  Parameters for improving treatment in MS must include efficacy, safety, and patient satisfaction with the given DMD.
authors.affiliation: Universidade Metropolitana de Santos, Departamento de Neurologia, Santos SP, Brasil;|Residência em Clínica Médica da Angiocorpore, Santos SP, Brasil;
authors.forename: Caroline Vieira
authors.initials: CV
authors.lastname: Spessotto
authors.affiliation: Instituto de Neurologia de Curitiba, Curitiba PR, Brasil;
authors.forename: Hanaie
authors.initials: H
authors.lastname: Cavalli
authors.affiliation: Centro Hospitalar Unimed, Joinville SC, Brasil;
authors.forename: Audred Cristina Biondo
authors.initials: AC
authors.lastname: Eboni
authors.affiliation: Hospital de Clinicas de Porto Alegre, Porto Alegre RS, Brasil;
authors.forename: Rafael Berlezi
authors.initials: RB
authors.lastname: Machado
authors.affiliation: Universidade Regional de Blumenau, Blumenau SC, Brasil.
authors.forename: Analara Munardi
authors.initials: AM
authors.lastname: Mousquer
authors.affiliation: Hospital de Clinicas de Porto Alegre, Porto Alegre RS, Brasil;
authors.forename: Lara Both
authors.initials: LB
authors.lastname: Palazzo
authors.affiliation: Hospital de Clinicas de Porto Alegre, Porto Alegre RS, Brasil;
authors.forename: Alessandro
authors.initials: A
authors.lastname: Finkelsztejn
authors.affiliation: Centro Hospitalar Unimed, Joinville SC, Brasil;
authors.forename: Marcus Vinicius Magno
authors.initials: MV
authors.lastname: Goncalves
authors.affiliation: Instituto de Neurologia de Curitiba, Curitiba PR, Brasil;
authors.forename: Henry Koiti
authors.initials: HK
authors.lastname: Sato
authors.affiliation: Universidade Regional de Blumenau, Blumenau SC, Brasil.
authors.forename: Fabio
authors.initials: F
authors.lastname: Siquineli
authors.affiliation: Universidade Metropolitana de Santos, Departamento de Neurologia, Santos SP, Brasil;
authors.forename: Yara Dadalti
authors.initials: YD
authors.lastname: Fragoso
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D017211:Treatment Failure
chemical_list: D007166:Immunosuppressive Agents